SPECIFIC AIMS The CHAVI-ID Operations and Management Support Component, (OMSC) will serve as a resource to the entire CHAVI-ID, providing overall management, coordination and supervision ofthe program. The CHAVI-ID director, Bart Haynes will serve as the leader of the OMSC, and experienced OMSC staff will be responsible for managing and coordinating the entire range of CHAVI-ID activities, monitoring progress and ensuring that the CHAVI-ID Scientific Agenda and Strategic Plan is developed, renewed, and implemented effectively and efficiently.
Specific Aims will include the following.
Aim 1. Provide overall management, coordination and supervision of programs within CHAVI-ID to optimally facilitate HIV-1 vaccine discovery and development.
Aim 2. Ensure timely financial accounting in CHAVI-ID Aim 3. Ensure compliance with all institutional and federal research guidelines. Management of the CHAVI-ID will require remarkably complex and timely coordination of finances, program management, facilities, research and development activities, and investigators across disciplines and institutions. The expertise this group has gained over the past 6 years in CHAVI, will ensure success in the management of CHAVI-ID.
Effective and timely financial and programmatic management are the key to the success for any scientific consortium. Ensuring the management of individual scientific projects, and having the ability to redirect funds in a timely manner as dictated by the science will facilitate HIV-1 vaccine development.
|Chen, Jia; Frey, Gary; Peng, Hanqin et al. (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 88:1249-58|
|Hraber, Peter; Seaman, Michael S; Bailer, Robert T et al. (2014) Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-9|
|Pollara, Justin; Bonsignori, Mattia; Moody, M Anthony et al. (2014) HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88:7715-26|
|Verkoczy, Laurent; Diaz, Marilyn (2014) Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS 9:224-34|
|Hwang, Kwan-Ki; Trama, Ashley M; Kozink, Daniel M et al. (2014) IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. PLoS One 9:e90725|
|Haynes, Barton F; Moody, M Anthony; Alam, Munir et al. (2014) Progress in HIV-1 vaccine development. J Allergy Clin Immunol 134:3-10; quiz 11|
|Holl, T Matt; Yang, Guang; Kuraoka, Masayuki et al. (2014) Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-79|
|Roederer, Mario; Keele, Brandon F; Schmidt, Stephen D et al. (2014) Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-8|
|Dennison, S Moses; Anasti, Kara M; Jaeger, Frederick H et al. (2014) Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. J Virol 88:9406-17|
|Fera, Daniela; Schmidt, Aaron G; Haynes, Barton F et al. (2014) Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci U S A 111:10275-80|
Showing the most recent 10 out of 48 publications